Skip to main content

Table 2 Multivariable cox proportional hazards models for predicting outcomes per 1 U/L increase of DPP4a

From: Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction

 

Unadjusted

Model 1

Model 2

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p

MACCE

1.00 (0.97–1.04)

0.93

1.02 (0.98–1.05)

0.33

1.01 (0.98–1.05)

0.53

CV mortality

1.01 (0.96–1.06)

0.71

1.03 (0.98–1.08)

0.26

1.01 (0.95–1.06)

0.83

Myocardial infarction

1.03 (0.95–1.10)

0.51

1.03 (0.96–1.11)

0.41

1.05 (0.96–1.15)

0.29

HF readmission

1.03 (0.97–1.09)

0.41

1.04 (0.98–1.11)

0.23

1.03 (0.96–1.11)

0.41

Stroke

0.97 (0.89–1.06)

0.52

0.99 (0.91–1.08)

0.78

0.99 (0.89–1.09)

0.78

Non-CV mortality

1.05 (0.98–1.12)

0.18

1.08 (1.00–1.16)

0.04

1.06 (0.97–1.16)

0.18

Repeated revascularization

1.02 (0.99–1.06)

0.22

1.02 (0.99–1.06)

0.26

1.02 (0.98–1.06)

0.31

MACCE (in non-T2DM)

0.99 (0.95–1.03)

0.49

1.00 (0.96–1.04)

0.91

0.98 (0.94–1.03)

0.48

MACCE (in T2DM)

1.04 (0.98–1.11)

0.18

1.05 (0.98–1.21)

0.16

1.16 (1.04–1.30)

0.01

  1. Model 1 adjusted for age and gender; Model 2 adjusted for Model 1 plus body mass index, creatinine, triglyceride, aspartate aminotransferase, CK-MB, NT-pro-brain natriuretic peptide, fasting plasma glucose, hypertension, smoking, previous myocardial infarction and use of ACEI, ARB, statin, β-blocker, calcium channel blocker and diuretics
  2. CI confidence interval, CV cardiovascular, DPP4a plasma dipeptidyl peptidase-4 activity, HF heart failure, HR hazard ratio, MACCE major adverse cardiac or cerebrovascular events, T2DM type 2 diabetes